z-logo
open-access-imgOpen Access
Cyclin D1 Antisense Oligonucleotide Inhibits Cell Growth Stimulated by Epidermal Growth Factor and Induces Apoptosis of Gastric Cancer Cells
Author(s) -
Saikawa Yoshiro,
Kubota Tetsuro,
Otani Yoshihide,
Kitajima Masaki,
Modlin Irvin M.
Publication year - 2001
Publication title -
japanese journal of cancer research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.035
H-Index - 141
eISSN - 1349-7006
pISSN - 0910-5050
DOI - 10.1111/j.1349-7006.2001.tb01065.x
Subject(s) - cyclin d1 , apoptosis , cancer research , cell growth , epidermal growth factor , cancer , cyclin d , growth factor , cancer cell , biology , microbiology and biotechnology , chemistry , cell culture , medicine , cell cycle , receptor , biochemistry , genetics
The cyclin Dl protein is one of the cell cycle regulators required for cell cycle progression through Gl phase to S phase. The cyclin Dl‐cyclin‐dependent kinase (CDK) system is thought to control the cell cycle through mediating extracellular signals from mitogens, such as epidermal growth factor (EGF). In this study, we attempted to examine the therapeutic effect of cyclin Dl antisense oligonucleotides (AS/D1) on cell proliferation and apoptosis of the gastric cancer cell line MKN‐74, in the presence and absence of EGF‐stimulation. Evaluation of cell survival and DNA synthesis revealed that enhanced cell growth following EGF‐stimulation was completely inhibited by a 24 h pre‐incubation with 100 nM AS/D1. This inhibition was down to 19.3% compared with maximal DNA synthesis after stimulation with 3 nM EGF alone. Western blotting demonstrated that while EGF‐stimulation led to cyclin Dl over‐expression, AS/D1 inhibited cyclin Dl protein expression. We also demonstrated the induction of apoptosis in MKN‐74 cells by AS/D1. In conclusion, EGF‐stimulated MKN‐74 cell proliferation was inhibited by AS/D1, which could overcome EGF‐induced cyclin Dl over‐expression. AS/D1 also affected cell survival by inducing apoptosis through cell cycle arrest following cyclin Dl depletion. Thus, AS/D1 may be a candidate for use as a novel cancer therapy specifically targeted against the over‐expression of cyclin Dl enhanced by EGF in malignant cells

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here